Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

$45.56

-2.5 (-5.20%)

, GSK

GlaxoSmithKline

$38.90

-0.63 (-1.59%)

07:04
08/11/17
08/11
07:04
08/11/17
07:04

Ionis Pharmaceuticals retains all rights to inotersen, IONIS-FB-L

Ionis Pharmaceuticals (IONS) reported that the company has retained all rights to inotersen and IONIS-FB-L. As part of a reprioritization of its pipeline and strategic review of its Rare Diseases business, GSK (GSK) declined its options on both drugs. Ionis plans to file for marketing authorization for inotersen this year to support a commercial launch of inotersen in 2018. Inotersen is a drug designed to treat patients with TTR amyloidosis. The first indication Ionis is pursuing for inotersen is to treat patients with polyneuropathy due to hereditary TTR amyloidosis. Ionis completed the Phase 3 NEURO-TTR study of inotersen in which the drug demonstrated significant benefit on both primary clinical endpoints of neurological disease progression and quality of life in patients with hATTR-PN.

IONS

Ionis Pharmaceuticals

$45.56

-2.5 (-5.20%)

GSK

GlaxoSmithKline

$38.90

-0.63 (-1.59%)

  • 24

    Oct

IONS Ionis Pharmaceuticals
$45.56

-2.5 (-5.20%)

07/27/17
BERN
07/27/17
INITIATION
BERN
Market Perform
Ionis Pharmaceuticals initiated with a Market Perform at Bernstein
Bernstein analyst Vincent Chen started coverage of Ionis with a $57 price target and a Market Perform rating.
07/26/17
BMOC
07/26/17
NO CHANGE
BMOC
Ionis Pharmaceuticals should be bought on weakness, says BMO Capital
BMO Capital analyst Do Kim recommends buying Ionis on weakness following Biogen's comments on Spinraza. The analyst thinks that Spinraza can grow in Type and Type 3. Kim keeps an Outperform rating on Ionis.
07/25/17
WELS
07/25/17
NO CHANGE
Target $75
WELS
Outperform
Ionis challenges to Spinraza dosing addressable, says Wells Fargo
Wells Fargo analyst Jim Birchenough noted that Ionis (IONS) partner Biogen (BIIB) made comments that suggested slowing growth for Spinraza in the future due to technical challenges to dosing in patients with spinal surgeries. However, he understands that Ionis has seen initial success in dosing patients with type 2 SMA and spinal surgery and believes these patients will be viable candidates for Spinraza even though the process is more involved. Birchenough, who thinks the drug's impressive growth and broadening use and reimbursement more than offsets a hurdle dosing certain patients, raised his price target on Ionis shares to $75 and keeps an Outperform rating on the stock.
07/25/17
NEED
07/25/17
NO CHANGE
NEED
Ionis selloff a buying opportunity, says Needham
Needham analyst Chad Messer recommends using today's selloff in shares of Ionis Pharmaceuticals (IONS) as a buying opportunity. He believes concerns over the sustainability of Biogen's (BIIB) Spinraza launch overlook the longer term opportunity. The analyst has Buy rating on Ionis shares, which are down 11% in midday trading to $53.16.
GSK GlaxoSmithKline
$38.90

-0.63 (-1.59%)

07/10/17
PIPR
07/10/17
NO CHANGE
Target $5
PIPR
Neutral
OncoMed termination from GSK not surprising, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes GlaxoSmithKline (GSK) terminating its agreement with OncoMed Pharmaceuticals (OMED) is not surprising since tarextumab, the only remaining asset under the collaboration, failed previously to meet the primary endpoint in a Phase II study for first-line small cell lung cancer. The analyst says he remains focused on OncoMed's early stage pipeline including navicixizumab, rosmantuzumab and I/O assets anti-TIGIT and GITR trimer. Tenthoff keeps a Neutral rating on OncoMed with a $5 price target.
07/05/17
07/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Capital One (COF) downgraded to Underperform from Neutral at Wedbush with analyst Henry Coffey saying ROE from operations is much lower than expected, and return on capital measures are sub-optimal. 2. Weyerhaeuser (WY) downgraded to Neutral from Buy at BofA/Merrill with analyst George Staphos saying his thesis has played out and catalysts are limited in the intermediate term. 3. Buffalo Wild Wings (BWLD) downgraded to Equal Weight from Overweight at Stephens with analyst Will Slabaugh saying the proxy fight and management shake-up has created uncertainty regarding the company's future and said a downward revision to guidance is likely due to continued margin pressures, soft topline trends, and lack of near-term catalysts. 4. GlaxoSmithKline (GSK) downgraded to Neutral from Buy at Citi with analyst Andrew Baum saying he believes the market is under-appreciating the slowing of the company's HIV market growth. 5. Oneok (OKE) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Tom Abrams saying risk/reward is balanced. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/05/17
SBSH
07/05/17
DOWNGRADE
SBSH
Neutral
GlaxoSmithKline downgraded to Neutral from Buy at Citi
Citi analyst Andrew Baum downgraded GlaxoSmithKline (GSK) to Neutral and lowered his price target for the shares to GBP 17 from GBP 18. The analyst believes the market is underappreciating the slowing of the company's HIV market growth. He prefers shares of AstraZeneca (AZN), Roche (RHHBY) and Bayer (BAYRY) for exposure to Europe.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

KSU

Kansas City Southern

$105.80

-0.07 (-0.07%)

17:45
08/18/17
08/18
17:45
08/18/17
17:45
Hot Stocks
Kansas City Southern director Henry Maier buys 3,000 shares »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

RXII

RXi Pharmaceuticals

$0.58

-0.02 (-3.36%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on RXi Pharmaceuticals »

RXi Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

WIN

Windstream

$1.98

0.06 (3.13%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Hot Stocks
Windstream CEO acquires 25,381 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$2.44

-0.22 (-8.27%)

17:27
08/18/17
08/18
17:27
08/18/17
17:27
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRN

Trinity Industries

$28.20

-0.03 (-0.11%)

17:25
08/18/17
08/18
17:25
08/18/17
17:25
Hot Stocks
ValueAct raises stake inTrinity Industries to 11% from 9.8% »

As of this date, ValueAct…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LPTN

Lpath

17:11
08/18/17
08/18
17:11
08/18/17
17:11
Hot Stocks
Breaking Hot Stocks news story on Lpath »

Stonepine Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PGR

Progressive

$48.63

0.12 (0.25%)

17:08
08/18/17
08/18
17:08
08/18/17
17:08
Hot Stocks
Progressive CFO sells 50,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$172.57

-0.32 (-0.19%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Thermo Fisher director sells 11,318 shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

SMBC

Southern Missouri Bancorp

$31.18

-0.05 (-0.16%)

17:06
08/18/17
08/18
17:06
08/18/17
17:06
Hot Stocks
Southern Missouri Bancorp and Southern Missouri Bancshares to merge »

Southern Missouri Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:58
08/18/17
08/18
16:58
08/18/17
16:58
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ended advisory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says ending…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:57
08/18/17
08/18
16:57
08/18/17
16:57
Hot Stocks
Breaking Hot Stocks news story on Icahn Enterprises »

Icahn says never had…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEP

Icahn Enterprises

$50.00

-0.2 (-0.40%)

16:56
08/18/17
08/18
16:56
08/18/17
16:56
Hot Stocks
Icahn no longer special advisor to President Trump on regulatory reform issues »

Carl Icahn, founder of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:55
08/18/17
08/18
16:55
08/18/17
16:55
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVTA

Invitae

$9.60

0.05 (0.52%)

16:49
08/18/17
08/18
16:49
08/18/17
16:49
Syndicate
Breaking Syndicate news story on Invitae »

Invitae files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$30.38

0.76 (2.57%)

16:48
08/18/17
08/18
16:48
08/18/17
16:48
Hot Stocks
Micron director sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 06

    Sep

INSY

Insys Therapeutics

$9.17

-0.11 (-1.19%)

16:42
08/18/17
08/18
16:42
08/18/17
16:42
Hot Stocks
Insys agrees to pay $4.45M to settle opioid marketing suit »

Illinois Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

16:34
08/18/17
08/18
16:34
08/18/17
16:34
Syndicate
Breaking Syndicate news story on Akari Therapeutics »

Akari Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JMBA

Jamba

$9.11

-0.04 (-0.44%)

16:32
08/18/17
08/18
16:32
08/18/17
16:32
Hot Stocks
Jamba receives expected letter from Nasdaq »

Jamba, Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIL

Hill International

$4.50

0.2 (4.65%)

16:31
08/18/17
08/18
16:31
08/18/17
16:31
Hot Stocks
Hill International receives NYSE notice regarding late Form 10-Q filing »

Hill International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$55.65

-0.47 (-0.84%)

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Periodicals
Target ends relationship with food startup Hampton Creek, Bloomberg says »

After an internal review,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
08/18/17
08/18
16:30
08/18/17
16:30
Options
Preliminary option volume of 23.2M today »

Preliminary option volume…

NBEV

New Age Beverages

$3.51

-0.49 (-12.25%)

16:29
08/18/17
08/18
16:29
08/18/17
16:29
Hot Stocks
New Age Beverages director sells nearly 42,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

, ESV

Ensco

$4.28

0.12 (2.88%)

16:24
08/18/17
08/18
16:24
08/18/17
16:24
Hot Stocks
Atwood Oceanics, Ensco file proxy materials in connection with pending merger »

Ensco (ESV) and Atwood…

ATW

Atwood Oceanics

$6.26

0.22 (3.64%)

ESV

Ensco

$4.28

0.12 (2.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$83.76

-0.1 (-0.12%)

16:23
08/18/17
08/18
16:23
08/18/17
16:23
Periodicals
Nestle faces potential fraud suit over Poland Spring marketing, WSJ says »

Nestle is facing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.